Last reviewed · How we verify
Latanoprost/Timolol therapy
Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism.
Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Latanoprost/Timolol therapy |
|---|---|
| Also known as | Xalacom |
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Prostaglandin analog / Beta-blocker combination |
| Target | Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors on the ciliary muscle, facilitating drainage of fluid from the eye through the unconventional uveoscleral pathway. Timolol is a non-selective beta-blocker that reduces aqueous humor secretion by the ciliary body. The combination provides additive intraocular pressure-lowering effects through complementary mechanisms.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Headache
- Bradycardia
- Fatigue
Key clinical trials
- Effect of IOP Lowering on Progressive HM (NA)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Latanoprost/Timolol therapy CI brief — competitive landscape report
- Latanoprost/Timolol therapy updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI